A case of COVID-19 reinfection in a hemodialysis patient: the role of antibody in SARS-CoV-2 infection
Hemodialysis patients are vulnerable to severe and lethal COVID-19, and their protective immunity against COVID-19 is not yet fully understood. Therefore, we report a case of COVID-19 reinfection in a hemodialysis patient 81 days after the first episode and discuss the role of antibodies in SARS-CoV...
Gespeichert in:
| Veröffentlicht in: | CEN case reports 2022-11, Vol.11 (4), p.422-427 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 427 |
|---|---|
| container_issue | 4 |
| container_start_page | 422 |
| container_title | CEN case reports |
| container_volume | 11 |
| creator | Beppu, Hiroko Ogawa, Toshie Ishikane, Masahiro Kawanishi, Tomoko Fukuda, Tatsuya Sato, Lubuna Matsunaga, Akihiro Maeda, Kenji Katagiri, Daisuke Ishizaka, Yukihito Mitsuya, Hiroaki Ohmagari, Norio Yasui, Fumihiko Kohara, Michinori Kikuchi, Kan Wakai, Sachiko |
| description | Hemodialysis patients are vulnerable to severe and lethal COVID-19, and their protective immunity against COVID-19 is not yet fully understood. Therefore, we report a case of COVID-19 reinfection in a hemodialysis patient 81 days after the first episode and discuss the role of antibodies in SARS-CoV-2 infection. A hemodialysis patient developed asymptomatic COVID-19 due to an outbreak in a hospital on October 29th, 2020. As he was hospitalized and did not develop any symptoms, he was discharged on November 9th. On January 18th, he presented with symptomatic COVID-19 due to close household contact. Then, he developed respiratory failure and was transferred to National Center for Global Health and Medicine if he would need intensive care. He recovered with oxygen inhalation, favipiravir, and steroid treatment, and was discharged on February 12th. To evaluate anti-SARS-CoV-2 antibodies during two hospital stays, we measured immunoglobulin (Ig) G specific for S1 subunit of Spike (S) protein of SARS-CoV-2 (IgG-S1) , IgG specific for the full-length S protein (anti-Spike IgG) and neutralizing antibodies. No seroconversion occurred 5 days after initial infection, the seroconversion of IgG-S1 was observed 10 days after the second infection. Similar to IgG-S1 antibody titer results, anti-Spike IgG and neutralizing antibodies increased from 12 days after the second infection. In conclusion, we experienced a case of COVID-19 reinfection in a hemodialysis patient 81 days after the first episode and showed the kinetics and role of antibodies in SARS-CoV-2 infection. Further studies are needed to understand SARS-CoV-2 reinfection risk in hemodialysis patients and its clinical significance. |
| doi_str_mv | 10.1007/s13730-022-00697-z |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8906520</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2638014183</sourcerecordid><originalsourceid>FETCH-LOGICAL-c476t-8e722893e4e31af474b0ea10caae1cbef6e1c59a5368c41e3a17ae4d3d6779d23</originalsourceid><addsrcrecordid>eNp9kU9PGzEQxVdVq4IoX6CHysdeTMd_1l73UClKaYuEhASUq-V4Z4nRxk7tTaXw6WsIjeDCaUaa996M5tc0HxmcMAD9pTChBVDgnAIoo-n9m-aQM8OplNK8fdYfNMel3AEAExJaMO-bA9FypcC0h80wI94VJGkg84ubs--UGZIxxAH9FFIkIRJHlrhKfXDjtoRC1m4KGKevZFoiyWl89Lo4hUXqtw_6q9nlFZ2nG8rJPudD825wY8Hjp3rU_P5xej3_Rc8vfp7NZ-fUS60m2qHmvDMCJQrmBqnlAtAx8M4h8wscVC2tca1QnZcMhWPaoexFr7Q2PRdHzbdd7nqzWGHv66HZjXadw8rlrU0u2JeTGJb2Nv21nQHVcqgBn58CcvqzwTLZVSgex9FFTJtiuRIdMMk6UaV8J_U5lZJx2K9hYB8Y2R0jWxnZR0b2vpo-PT9wb_lPpArETlDqKN5itndpk2N92mux_wAVAJ0F</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2638014183</pqid></control><display><type>article</type><title>A case of COVID-19 reinfection in a hemodialysis patient: the role of antibody in SARS-CoV-2 infection</title><source>SpringerLink Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Beppu, Hiroko ; Ogawa, Toshie ; Ishikane, Masahiro ; Kawanishi, Tomoko ; Fukuda, Tatsuya ; Sato, Lubuna ; Matsunaga, Akihiro ; Maeda, Kenji ; Katagiri, Daisuke ; Ishizaka, Yukihito ; Mitsuya, Hiroaki ; Ohmagari, Norio ; Yasui, Fumihiko ; Kohara, Michinori ; Kikuchi, Kan ; Wakai, Sachiko</creator><creatorcontrib>Beppu, Hiroko ; Ogawa, Toshie ; Ishikane, Masahiro ; Kawanishi, Tomoko ; Fukuda, Tatsuya ; Sato, Lubuna ; Matsunaga, Akihiro ; Maeda, Kenji ; Katagiri, Daisuke ; Ishizaka, Yukihito ; Mitsuya, Hiroaki ; Ohmagari, Norio ; Yasui, Fumihiko ; Kohara, Michinori ; Kikuchi, Kan ; Wakai, Sachiko</creatorcontrib><description>Hemodialysis patients are vulnerable to severe and lethal COVID-19, and their protective immunity against COVID-19 is not yet fully understood. Therefore, we report a case of COVID-19 reinfection in a hemodialysis patient 81 days after the first episode and discuss the role of antibodies in SARS-CoV-2 infection. A hemodialysis patient developed asymptomatic COVID-19 due to an outbreak in a hospital on October 29th, 2020. As he was hospitalized and did not develop any symptoms, he was discharged on November 9th. On January 18th, he presented with symptomatic COVID-19 due to close household contact. Then, he developed respiratory failure and was transferred to National Center for Global Health and Medicine if he would need intensive care. He recovered with oxygen inhalation, favipiravir, and steroid treatment, and was discharged on February 12th. To evaluate anti-SARS-CoV-2 antibodies during two hospital stays, we measured immunoglobulin (Ig) G specific for S1 subunit of Spike (S) protein of SARS-CoV-2 (IgG-S1) , IgG specific for the full-length S protein (anti-Spike IgG) and neutralizing antibodies. No seroconversion occurred 5 days after initial infection, the seroconversion of IgG-S1 was observed 10 days after the second infection. Similar to IgG-S1 antibody titer results, anti-Spike IgG and neutralizing antibodies increased from 12 days after the second infection. In conclusion, we experienced a case of COVID-19 reinfection in a hemodialysis patient 81 days after the first episode and showed the kinetics and role of antibodies in SARS-CoV-2 infection. Further studies are needed to understand SARS-CoV-2 reinfection risk in hemodialysis patients and its clinical significance.</description><identifier>ISSN: 2192-4449</identifier><identifier>EISSN: 2192-4449</identifier><identifier>DOI: 10.1007/s13730-022-00697-z</identifier><identifier>PMID: 35266095</identifier><language>eng</language><publisher>Singapore: Springer Nature Singapore</publisher><subject>Case Report ; Medicine ; Medicine & Public Health ; Nephrology ; Urology</subject><ispartof>CEN case reports, 2022-11, Vol.11 (4), p.422-427</ispartof><rights>The Author(s) under exclusive licence to The Japan Society of Nephrology 2022</rights><rights>2022. The Author(s) under exclusive licence to The Japan Society of Nephrology.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c476t-8e722893e4e31af474b0ea10caae1cbef6e1c59a5368c41e3a17ae4d3d6779d23</cites><orcidid>0000-0002-6872-2857</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8906520/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8906520/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,41464,42533,51294,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35266095$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Beppu, Hiroko</creatorcontrib><creatorcontrib>Ogawa, Toshie</creatorcontrib><creatorcontrib>Ishikane, Masahiro</creatorcontrib><creatorcontrib>Kawanishi, Tomoko</creatorcontrib><creatorcontrib>Fukuda, Tatsuya</creatorcontrib><creatorcontrib>Sato, Lubuna</creatorcontrib><creatorcontrib>Matsunaga, Akihiro</creatorcontrib><creatorcontrib>Maeda, Kenji</creatorcontrib><creatorcontrib>Katagiri, Daisuke</creatorcontrib><creatorcontrib>Ishizaka, Yukihito</creatorcontrib><creatorcontrib>Mitsuya, Hiroaki</creatorcontrib><creatorcontrib>Ohmagari, Norio</creatorcontrib><creatorcontrib>Yasui, Fumihiko</creatorcontrib><creatorcontrib>Kohara, Michinori</creatorcontrib><creatorcontrib>Kikuchi, Kan</creatorcontrib><creatorcontrib>Wakai, Sachiko</creatorcontrib><title>A case of COVID-19 reinfection in a hemodialysis patient: the role of antibody in SARS-CoV-2 infection</title><title>CEN case reports</title><addtitle>CEN Case Rep</addtitle><addtitle>CEN Case Rep</addtitle><description>Hemodialysis patients are vulnerable to severe and lethal COVID-19, and their protective immunity against COVID-19 is not yet fully understood. Therefore, we report a case of COVID-19 reinfection in a hemodialysis patient 81 days after the first episode and discuss the role of antibodies in SARS-CoV-2 infection. A hemodialysis patient developed asymptomatic COVID-19 due to an outbreak in a hospital on October 29th, 2020. As he was hospitalized and did not develop any symptoms, he was discharged on November 9th. On January 18th, he presented with symptomatic COVID-19 due to close household contact. Then, he developed respiratory failure and was transferred to National Center for Global Health and Medicine if he would need intensive care. He recovered with oxygen inhalation, favipiravir, and steroid treatment, and was discharged on February 12th. To evaluate anti-SARS-CoV-2 antibodies during two hospital stays, we measured immunoglobulin (Ig) G specific for S1 subunit of Spike (S) protein of SARS-CoV-2 (IgG-S1) , IgG specific for the full-length S protein (anti-Spike IgG) and neutralizing antibodies. No seroconversion occurred 5 days after initial infection, the seroconversion of IgG-S1 was observed 10 days after the second infection. Similar to IgG-S1 antibody titer results, anti-Spike IgG and neutralizing antibodies increased from 12 days after the second infection. In conclusion, we experienced a case of COVID-19 reinfection in a hemodialysis patient 81 days after the first episode and showed the kinetics and role of antibodies in SARS-CoV-2 infection. Further studies are needed to understand SARS-CoV-2 reinfection risk in hemodialysis patients and its clinical significance.</description><subject>Case Report</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Nephrology</subject><subject>Urology</subject><issn>2192-4449</issn><issn>2192-4449</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp9kU9PGzEQxVdVq4IoX6CHysdeTMd_1l73UClKaYuEhASUq-V4Z4nRxk7tTaXw6WsIjeDCaUaa996M5tc0HxmcMAD9pTChBVDgnAIoo-n9m-aQM8OplNK8fdYfNMel3AEAExJaMO-bA9FypcC0h80wI94VJGkg84ubs--UGZIxxAH9FFIkIRJHlrhKfXDjtoRC1m4KGKevZFoiyWl89Lo4hUXqtw_6q9nlFZ2nG8rJPudD825wY8Hjp3rU_P5xej3_Rc8vfp7NZ-fUS60m2qHmvDMCJQrmBqnlAtAx8M4h8wscVC2tca1QnZcMhWPaoexFr7Q2PRdHzbdd7nqzWGHv66HZjXadw8rlrU0u2JeTGJb2Nv21nQHVcqgBn58CcvqzwTLZVSgex9FFTJtiuRIdMMk6UaV8J_U5lZJx2K9hYB8Y2R0jWxnZR0b2vpo-PT9wb_lPpArETlDqKN5itndpk2N92mux_wAVAJ0F</recordid><startdate>20221101</startdate><enddate>20221101</enddate><creator>Beppu, Hiroko</creator><creator>Ogawa, Toshie</creator><creator>Ishikane, Masahiro</creator><creator>Kawanishi, Tomoko</creator><creator>Fukuda, Tatsuya</creator><creator>Sato, Lubuna</creator><creator>Matsunaga, Akihiro</creator><creator>Maeda, Kenji</creator><creator>Katagiri, Daisuke</creator><creator>Ishizaka, Yukihito</creator><creator>Mitsuya, Hiroaki</creator><creator>Ohmagari, Norio</creator><creator>Yasui, Fumihiko</creator><creator>Kohara, Michinori</creator><creator>Kikuchi, Kan</creator><creator>Wakai, Sachiko</creator><general>Springer Nature Singapore</general><general>Springer Singapore</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-6872-2857</orcidid></search><sort><creationdate>20221101</creationdate><title>A case of COVID-19 reinfection in a hemodialysis patient: the role of antibody in SARS-CoV-2 infection</title><author>Beppu, Hiroko ; Ogawa, Toshie ; Ishikane, Masahiro ; Kawanishi, Tomoko ; Fukuda, Tatsuya ; Sato, Lubuna ; Matsunaga, Akihiro ; Maeda, Kenji ; Katagiri, Daisuke ; Ishizaka, Yukihito ; Mitsuya, Hiroaki ; Ohmagari, Norio ; Yasui, Fumihiko ; Kohara, Michinori ; Kikuchi, Kan ; Wakai, Sachiko</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c476t-8e722893e4e31af474b0ea10caae1cbef6e1c59a5368c41e3a17ae4d3d6779d23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Case Report</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Nephrology</topic><topic>Urology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Beppu, Hiroko</creatorcontrib><creatorcontrib>Ogawa, Toshie</creatorcontrib><creatorcontrib>Ishikane, Masahiro</creatorcontrib><creatorcontrib>Kawanishi, Tomoko</creatorcontrib><creatorcontrib>Fukuda, Tatsuya</creatorcontrib><creatorcontrib>Sato, Lubuna</creatorcontrib><creatorcontrib>Matsunaga, Akihiro</creatorcontrib><creatorcontrib>Maeda, Kenji</creatorcontrib><creatorcontrib>Katagiri, Daisuke</creatorcontrib><creatorcontrib>Ishizaka, Yukihito</creatorcontrib><creatorcontrib>Mitsuya, Hiroaki</creatorcontrib><creatorcontrib>Ohmagari, Norio</creatorcontrib><creatorcontrib>Yasui, Fumihiko</creatorcontrib><creatorcontrib>Kohara, Michinori</creatorcontrib><creatorcontrib>Kikuchi, Kan</creatorcontrib><creatorcontrib>Wakai, Sachiko</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>CEN case reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Beppu, Hiroko</au><au>Ogawa, Toshie</au><au>Ishikane, Masahiro</au><au>Kawanishi, Tomoko</au><au>Fukuda, Tatsuya</au><au>Sato, Lubuna</au><au>Matsunaga, Akihiro</au><au>Maeda, Kenji</au><au>Katagiri, Daisuke</au><au>Ishizaka, Yukihito</au><au>Mitsuya, Hiroaki</au><au>Ohmagari, Norio</au><au>Yasui, Fumihiko</au><au>Kohara, Michinori</au><au>Kikuchi, Kan</au><au>Wakai, Sachiko</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A case of COVID-19 reinfection in a hemodialysis patient: the role of antibody in SARS-CoV-2 infection</atitle><jtitle>CEN case reports</jtitle><stitle>CEN Case Rep</stitle><addtitle>CEN Case Rep</addtitle><date>2022-11-01</date><risdate>2022</risdate><volume>11</volume><issue>4</issue><spage>422</spage><epage>427</epage><pages>422-427</pages><issn>2192-4449</issn><eissn>2192-4449</eissn><abstract>Hemodialysis patients are vulnerable to severe and lethal COVID-19, and their protective immunity against COVID-19 is not yet fully understood. Therefore, we report a case of COVID-19 reinfection in a hemodialysis patient 81 days after the first episode and discuss the role of antibodies in SARS-CoV-2 infection. A hemodialysis patient developed asymptomatic COVID-19 due to an outbreak in a hospital on October 29th, 2020. As he was hospitalized and did not develop any symptoms, he was discharged on November 9th. On January 18th, he presented with symptomatic COVID-19 due to close household contact. Then, he developed respiratory failure and was transferred to National Center for Global Health and Medicine if he would need intensive care. He recovered with oxygen inhalation, favipiravir, and steroid treatment, and was discharged on February 12th. To evaluate anti-SARS-CoV-2 antibodies during two hospital stays, we measured immunoglobulin (Ig) G specific for S1 subunit of Spike (S) protein of SARS-CoV-2 (IgG-S1) , IgG specific for the full-length S protein (anti-Spike IgG) and neutralizing antibodies. No seroconversion occurred 5 days after initial infection, the seroconversion of IgG-S1 was observed 10 days after the second infection. Similar to IgG-S1 antibody titer results, anti-Spike IgG and neutralizing antibodies increased from 12 days after the second infection. In conclusion, we experienced a case of COVID-19 reinfection in a hemodialysis patient 81 days after the first episode and showed the kinetics and role of antibodies in SARS-CoV-2 infection. Further studies are needed to understand SARS-CoV-2 reinfection risk in hemodialysis patients and its clinical significance.</abstract><cop>Singapore</cop><pub>Springer Nature Singapore</pub><pmid>35266095</pmid><doi>10.1007/s13730-022-00697-z</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0002-6872-2857</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2192-4449 |
| ispartof | CEN case reports, 2022-11, Vol.11 (4), p.422-427 |
| issn | 2192-4449 2192-4449 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8906520 |
| source | SpringerLink Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| subjects | Case Report Medicine Medicine & Public Health Nephrology Urology |
| title | A case of COVID-19 reinfection in a hemodialysis patient: the role of antibody in SARS-CoV-2 infection |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T00%3A23%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20case%20of%20COVID-19%20reinfection%20in%20a%20hemodialysis%20patient:%20the%20role%20of%20antibody%20in%20SARS-CoV-2%20infection&rft.jtitle=CEN%20case%20reports&rft.au=Beppu,%20Hiroko&rft.date=2022-11-01&rft.volume=11&rft.issue=4&rft.spage=422&rft.epage=427&rft.pages=422-427&rft.issn=2192-4449&rft.eissn=2192-4449&rft_id=info:doi/10.1007/s13730-022-00697-z&rft_dat=%3Cproquest_pubme%3E2638014183%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2638014183&rft_id=info:pmid/35266095&rfr_iscdi=true |